Base excision repair (BER) inhibitor TRC 102 (Methoxyamine) combined with pemetrexed (PEM)-based chemo-radiation (CRT) for locally advanced non-squamous non-small cell lung cancer (NS-NSCLC): Results of a phase I trial.

Authors

Tithi Biswas

University Hospitals Seidman Cancer Center, Case Western Reserve University, Cleveland, OH

Tithi Biswas , Afshin Dowlati , Charles Kunos , John Pink , Nancy Oleinick , Shakun M. Malik , Pingfu Fu , Debora S. Bruno , David Lawrence Bajor , Monaliben Patel , Mitchell Machtay

Sign-In to See More Abstracts, Journal Articles, Posters, Videos and Slides and to Bookmark Your Favorite Content.

Sign-In

Similar Posters

insert_chart_outlined

Poster

2021 ASCO Annual Meeting

bookmark_border

Randomized phase III Trial of MEDI4736 (durvalumab) as concurrent and consolidative therapy or consolidative therapy alone for unresectable stage 3 NSCLC: A trial of the ECOG-ACRIN Cancer Research Group (EA5181).

First Author: John M. Varlotto

insert_chart_outlined

Poster

2015 ASCO Annual Meeting

bookmark_border

Phase I study of vorinostat with concurrent chemoradiotherapy (CRT) for locally advanced non-squamous non-small cell lung cancer (NSCLC).

First Author: Ranee Mehra

insert_chart_outlined

Poster

2018 ASCO Annual Meeting

bookmark_border

A phase I dose-finding study of metformin in combination with concurrent cisplatin and radiation in patients with locally advanced head and neck squamous cell carcinoma.

First Author: Shuchi Gulati

insert_chart_outlined

Poster

2014 Gastrointestinal Cancers Symposium

bookmark_border

Phase I study of concomitant pemetrexed and cisplatin plus radiation in patients with locally advanced or metastatic esophageal or gastroesophageal junction (GEJ) carcinomas.

First Author: Hani M. Babiker